BioStock: Stayble sums up and looks ahead

In Stayble Therapeutics’ half-year report, the company’s CEO Andreas Gerward describes 2022 as a successful year so far. Patient recruitment to the phase IIb study with STA363 is progressing at a rapid pace and the last patients are expected to be recruited shortly. In addition, the company plans to intensify partnering activities during the autumn and prepare for the regulatory process in the US, the company’s most important market. Gerward tells us more about the plans and his views on the first half of 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/08/stayble-sums-up-and-looks-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se